Efficacy of Guizhi Fuling Wan for primary dysmenorrhea: protocol for a randomized controlled trial

• DOI: 10.1186/s13063-021-05834-0
• Publication Date: 2021-12-18T12:02:37Z
• Authors: Yun Du; Yatong Li; Xianyun Fu; Chenjie Li; Luo Yanan
• Keywords: Medicine (General); China; Guizhi Fuling Wan; 3. Good health; Study Protocol; 03 medical and health sciences; R5-920; 0302 clinical medicine; Dysmenorrhea; Randomized controlled trial; Control; Humans; Family; Female; Primary dysmenorrhea; Placebo; Drugs, Chinese Herbal; Randomized Controlled Trials as Topic

Abstract Background Primary dysmenorrhea (PD) is one of the main gynecological complaints in women of child-bearing age, but limited effective treatments are available. Guizhi Fuling Wan (GFW), one of the most widely known traditional Chinese medicine (TCM) formulations, has been commonly used in clinical practice to treat gynecological disorders in China. In recent years, a growing number of studies have shown that GFW is beneficial for patients with PD. However, the quality of evidence is limited, and there are few studies on specific TCM syndromes of GFW for PD. Therefore, we plan to conduct a randomized controlled trial to explore the efficacy and safety of GFW for PD patients with heat-burning blood-stasis syndrome.

Methods and analysis The clinical study is a randomized, double-blinded, placebo-controlled trial. Eligible patients will be randomly assigned to the GFW group (treated with GFW) and the control group (treated with a matching placebo) in a 1:1 ratio for three menstrual cycles with a 3-month follow-up. The primary outcome will be the mean change of pain intensity measured by the visual analog scale (VAS). The secondary outcomes will include the Cox Menstrual Symptom Scale (CMSS), the Self-rating Depression Scale (SDS), the Self-rating Anxiety Scale (SAS), and the TCM syndrome scale. Adverse events will also be reported.

Discussion This randomized trial will be the first rigorous study designed to assess the efficacy and safety of GFW in treating PD with heat-burning blood-stasis syndrome. The finding of this study will provide an objective clinical basis for the use of GFW for PD in the future.

Trial registration Chinese Clinical Trial Registry ChiCTR2000034118. Registered on 24 June 2020